Shares of Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA – Get Free Report ) have received an average recommendation of “Hold” from the five research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.6667.
A number of research analysts have recently issued reports on VRCA shares. Lake Street Capital assumed coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective on the stock. HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen lowered Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th.
Get Our...